Sage Journals: Discover world-class research

Abstract

Objective:

Alvimopan use has reduced the length of hospital stay in patients undergoing major abdominal surgeries and radical cystectomy. Retroperitoneal lymph node dissection for testicular cancer may be associated with delayed gastrointestinal recovery prolonging hospital length of stay. We evaluate whether alvimopan is associated with enhanced gastrointestinal recovery and shorter hospital length of stay in men undergoing retroperitoneal lymph node dissection for testicular cancer.

Materials and methods:

From 2010 to 2016, 29 patients underwent open, transperitoneal bilateral template retroperitoneal lymph node dissection. Data for patients who received alvimopan were prospectively collected and compared to a historical cohort of patients who did not receive alvimopan. Primary outcome measures were length of stay and recovery of gastrointestinal function. Descriptive statistics were reported. Time-to-event outcomes were evaluated using cumulative incidence curves and log rank test. Factors associated with length of stay were analyzed for correlation using multiple linear regression.

Results:

Of 29 men undergoing retroperitoneal lymph node dissection, eight received alvimopan and 21 did not. The two cohorts were well matched, with no significant differences. In the alvimopan cohort compared with those who did not receive alvimopan median time to return of flatus was 2 versus 4 days (p=0.0002), and median time to first bowel movement was 2.5 versus 5 days (p=0.046), respectively. Median length of stay in the alvimopan cohort was 4 days versus 6 days in those who did not receive alvimopan (p=0.074). In adjusted analyses, receipt of alvimopan did not influence length of stay.

Conclusion:

Alvimopan may facilitate gastrointestinal recovery after retroperitoneal lymph node dissection for testicular cancer. Whether this translates into reduced length of stay needs to be determined by randomized controlled trials using larger cohorts.

Level of evidence:

3b.

Keywords

Alvimopan gastrointestinal recovery length of hospital stay retroperitoneal lymph node dissection testicular cancer

Get full access to this article

View all access options for this article.

References

Siegel

Miller

Fedewa

et al . Colorectal cancer statistics, 2017. CA Cancer J Clin 2017; 67: 177–193.

Einhorn

LH.

Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8: 1777–1781.

Carver

Serio

Bajorin

et al . Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol 2007; 25: 5603–5608.

National Cancer Institute. SEER Stat fact sheets: testis cancer. https://seer.cancer.gov/statfacts/html/testis.html (accessed 30 June 2018).

Baniel

Foster

Rowland

et al . Complications of primary retroperitoneal lymph node dissection. J Urol 1994; 152 (2 Pt 1): 424–427.

Heidenreich

Albers

Hartmann

et al . Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 2003; 169: 1710–1714.

Subramanian

Nguyen

Stephenson

et al . Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol 2010; 28: 504–509.

Stephenson

Sheinfeld

The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urol Oncol 2004; 22: 225–233; discussion 234–225.

Baniel

Foster

Rowland

et al . Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 1995; 153 (3 Pt 2): 976–980.

10.

Heidenreich

Thuer

Polyakov

Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol 2008; 53: 260–272.

11.

Delaney

Senagore

Viscusi

et al . Postoperative upper and lower gastrointestinal recovery and gastrointestinal morbidity in patients undergoing bowel resection: pooled analysis of placebo data from 3 randomized controlled trials. Am J Surg 2006; 191: 315–319.

12.

Baig

Wexner

SD.

Postoperative ileus: a review. Dis Colon Rectum 2004; 47: 516–526.

13.

Syan-Bhanvadia

Bazargani

Clifford

et al . Midline extraperitoneal approach to retroperitoneal lymph node dissection in testicular cancer: minimizing surgical morbidity. Eur Urol 2017; 72: 814–820.

14.

McNicol

Boyce

Schumann

et al . Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev 2008; 2: CD006332.

15.

Sultan

Coles

Dahm

Alvimopan for recovery of bowel function after radical cystectomy. Cochrane Database Syst Rev 2017; 5: CD012111.

16.

Lee

Chang

Kamat

et al . Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol 2014; 66: 265–272.

17.

Daneshmand

Ahmadi

Schuckman

et al . Enhanced recovery protocol after radical cystectomy for bladder cancer. J Urol 2014; 192: 50–55.

18.

US Food and Drug Administration (FDA). Alvimopan prescribing information. 2008. www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf (accessed 30 June 2018).

19.

Taguchi

Sharma

Saleem

et al . Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 2001; 345: 935–940.

20.

Kauf

Svatek

Amiel

et al . Alvimopan, a peripherally acting mu-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. J Urol 2014; 191: 1721–1727.

21.

Viscusi

Goldstein

Witkowski

et al . Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc 2006; 20: 64–70.

22.

Wolff

Michelassi

Gerkin

et al . Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004; 240: 728–734; discussion 734–725.

23.

Kraft

Maclaren

et al . Alvimopan (entereg) for the management of postoperative ileus in patients undergoing bowel resection. P T 2010; 35: 44–49.

24.

Hamilton

Parker

Griffin

et al . Alvimopan in an enhanced recovery program following radical cystectomy. Bladder Cancer 2015; 1: 137–142.

25.

Ludwig

Viscusi

Wolff

et al . Alvimopan for the management of postoperative ileus after bowel resection: characterization of clinical benefit by pooled responder analysis. World J Surg 2010; 34: 2185–2190.

26.

Manger

Nelson

Blanchard

et al . Alvimopan: a cost-effective tool to decrease cystectomy length of stay. Cent Eur J Urol 2014; 67: 335–341.

Effect of alvimopan on gastrointestinal recovery and length of hospital stay after retroperitoneal lymph node dissection for testicular cancer

Abstract

Objective:

Materials and methods:

Results:

Conclusion:

Level of evidence:

Keywords

Get full access to this article

References